B+
Bull case
28%
Probability
Target price
$88.00
+32.8% vs current
HALO
Halozyme TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
47%
Probability
Target price
$79.00
+19.2% vs current
B-
Bear case
25%
Probability
Target price
$60.00
-9.5% vs current
AI sentiment snapshot
Latest data as of 2026-05-14
Recent news sentiment (30D)
+0.3
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+64.9
Score
AI commentary
Near-term news tone is positive because company and AP-covered earnings materials framed Q1 as a beat with reiterated guidance and a larger buyback. However, this was a T+3 follow-up run with only modest additional trusted reaction available, and exact multi-day post-print price follow-through plus broad analyst revision breadth were not independently confirmed in checked sources as of May 14, 2026. That keeps the memo in cautious monitoring territory rather than a high-conviction upgrade.
RankAlpha Sentiment Codex - 2026-05-14
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-11catalystQ1 beat, reiterated 2026 outlook, and accelerated capital returnMedium impact
Halozyme's May 11 earnings release showed Q1 revenue up 42% year over year to $376.7 million, royalty revenue up 43% to $241 million, GAAP EPS of $1.22, non-GAAP EPS of $1.60, reiterated 2026 guidance, and a new $1 billion repurchase authorization with at least $400 million expected in 2026 [#8-K-2026-05-11].
2026-05-31eventPartner milestone flow broadened in MayMedium impact
The same company release highlighted FDA approval of argenx's sBLA for VYVGART Hytrulo in broader gMG and a new GSK global collaboration for ENHANZE across multiple oncology targets, adding near-term proof points that the platform is still expanding beyond the existing royalty base [#8-K-2026-05-11].
2026-12-31catalystDevelopment funnel still points to additional royalty wavesHigh impact
Management said two new Phase 1 starts brought ENHANZE products in development to nine and kept the company on track for 13 by year-end 2026, with approvals for that wave projected from 2029 onward; five signed Hypercon agreements covering 17 targets were framed as a later royalty wave in 2030/2031 timing [#8-K-2026-05-11].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-14 • Updated nightlySource: Internal modelMethodology